XML 72 R40.htm IDEA: XBRL DOCUMENT
v3.22.1

Collaborative and Other Relationships (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration |
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2022 |  | 2021 |  |  |  |
Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat |  | $ | 77.0 |  |  | $ | 55.5 |  |  |  |  |
Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income |  | 38.5 |  |  | 27.7 |  |  |  |  |
Total sales and marketing expense incurred by the Lecanemab Collaboration |  | 15.9 |  |  | 5.7 |  |  |  |  |
Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 8.0 |  |  | 2.9 |  |  |  |  |
Summary of Activity Related to Aducanumab Collaboration | A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2022 |  | 2021 |  |  |  |
Total ADUHELM development expense |  | $ | 44.2 |  |  | $ | 47.0 |  |  |  |  |
Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income |  | 24.3 |  |  | 25.8 |  |  |  |  |
Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement |  | 95.0 |  |  | 111.8 |  |  |  |  |
Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income |  | 50.9 |  |  | 60.3 |  |  |  |  |
Summary of Activity Related to Denali Therapeutics Collaboration | A summary of development expense related to this collaboration is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2022 |  | 2021 |  |  |  |
Total Denali collaboration development expense |  | $ | 14.9 |  |  | $ | 15.4 |  |  |  |  |
Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income |  | 8.9 |  |  | 9.2 |  |  |  |  |

X
- Definition Summary of Activity Related to Denali Therapeutics Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration